Asahi Songwon Colors LtdQ1 FY24
Asahi Songwon Colors Ltd Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹266P/E: 18.8Market Cap: ₹291 CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
Yes
Order
N/A
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →The Blue business is expected to remain a cash cow with no major capex; moderate growth around 10% is unlikely.
- →Peak capacity turnover around INR 800 crores group-wide is possible, with expected revenue between INR 700-750 crores in 2-3 years after ramp-up.
- →Chhatral facility external sales expected to reach INR 200 crores at peak.
- →Dahej AZO dyes segment targeting to increase from INR ~45 crores to ~INR 90 crores in FY24, driven mainly by domestic sales and expanding yellow pigment capacity.
- →Yellow pigments expected to dominate 70-75% of turnover for next 3 years, with capacity expansion underway.
- →New small molecule API products (2-4) to be launched gradually; however, these won't significantly impact top-line immediately.
- →Pregabalin remains key API product with plans for backward integration and approvals for export markets to improve margins and utilization over 3 years.
- →Overall target is 15-17% EBITDA margins on normalized peak revenues.
Margin guidance
Category 3- →The worst quarters are behind, with Q1 FY24 (April-June) expected better than Q4 FY23; no similar downturn anticipated again.
- →Business is bottoming out with global supply chain inventory at lows; demand revival expected leading to recovery of cash cow (Blue business).
- →Peak capacity turnover estimated around INR 800 crores on group basis, with more realistic INR 700-750 crores achievable, maintaining 15-17% EBITDA margins long term.
- →AZO segment expected to grow from ~INR 41 crores to INR 90 crores in FY24, driven by increased volumes and new shifts.
- →Chhatral plant to contribute INR 200 crores top-line (external sales) at peak, supporting backward integration and margin improvement in API segment.
- →API business (dominated by pregabalin) expected to consolidate and grow via approvals for regulated markets over 3-5 years, introducing higher value products.
- →Overall, confidence expressed for revenue and profit improvement in coming quarters and years, aiming for INR 1,000 crores turnover in medium term.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →There was a suggestion for a smaller rights issue of INR 30-40 crores to improve liquidity; this has been considered internally by the team.
- →No explicit confirmation of immediate fundraising via debt or equity was provided during the call.
- →Management indicated no need to defer acquisitions or capital expenditures, implying sufficient current liquidity and no urgent requirement for fresh funding.
- →Planned capex is limited to ongoing projects (Atlas Chhatral and ATC), totaling around INR 40 crores, after which the company intends to enter a consolidation phase lasting at least a year and a half with no new capex.
- →Management expects to de-lever the balance sheet in a planned fashion post peak capex.
- →No mention of new large-scale debt raising; existing debt peaks at INR 210 crores and is to be reduced afterward.
Order book
- →No explicit mention of current or expected orderbook or pending orders is provided on page 28 or related pages.
- →However, references indicate ongoing customer approvals and business ramp-ups:
- → - European and U.S. customers are in testing phases; it may take about six months for some to start orders (Page 27).
- → - Revival and increased demand expected from European customers such as Sun, Siegwerk, and Clariant (Page 15-18).
- → - Current business from European customers is minimal except for TTC, with around 90% sales in India for AZO dyes segment (Page 20).
- →The company is confident of improved results in coming quarters and expects consolidation phase by second half of 2024 (Page 28).
- →New product launches and expansions (Chhatral plant, Dahej yellow line expansion) will support future order growth (Pages 19-26).
Capex plans
Yes- →Current capex includes INR 70 crores investment in the Chhatral plant aimed at backward integration for the API business, expected to achieve around INR 200 crores external sales at peak.
- →Additional capex of about INR 30 crores is planned for doubling AZO dye capacities, particularly yellow, adding approx. 1,200 tons capacity with INR 10-14 crores capex; expansion expected to complete within 8-9 months.
- →No new capital expenditure planned beyond the two ongoing projects (Atlas Chhatral and ATC) for at least one to two years; company will enter a consolidation phase post-completion.
- →Plans to invest in renewable energy (wind and solar) are mentioned but no significant capex is planned currently for these.
- →Management is considering a smaller rights issue (INR 30-40 crores) to boost liquidity.
- →Focus over the next 3-5 years is on ramping up multiple products at various locations, aiming for INR 1,000 crores revenue goal.
How does Asahi Songwon Colors Ltd rank vs peers in Chemicals & Petrochemicals?
Pro feature1Asahi Songwon Colors Ltd
Rev 3Mar 3
See full Chemicals & Petrochemicals sector rankings
